Amgen (AMGN) currently presents as a for most investors, though it remains a top-tier choice for those seeking a mix of steady dividends and high-potential pipeline updates. As of late April 2026, the stock is navigating a transition from legacy blockbusters to next-generation therapies in obesity and oncology. Amgen Inc (AMGN) 30.22% since Jan 4, 2025 Closed: 23:00 • Disclaimer After hours: 03:00 Apr 27, 2026 Open342.35 Mkt cap$183.57B USD 52-wk high391.29 High348.04 P/E ratio23.91 52-wk low261.43 Div yield2.96% The Investment Thesis: Growth vs. Defense
The company recently declared a $2.52 per share quarterly dividend, offering an attractive yield of approximately 2.9-3% . is amgen a good stock to buy
Amgen's appeal lies in its ability to generate massive cash flow while aggressively pivoting its portfolio to offset upcoming biosimilar competition. The Bull Case Amgen (AMGN) currently presents as a for most